Tiefenbacher Pharmaceuticals launch of generic Teriflunomide
New market launch by Tiefenbacher Pharmaceuticals: Generic version of Teriflunomide in more than 20 European countries.
We are thrilled to announce that we have successfully prepared a day one launch of the generic version of Multiple Sclerosis (MS) medication Teriflunomide (reference brand name: Aubagio).
This complex generic launch follows Tiefenbacher`s strategy to make high quality pharmaceuticals better affordable and better available for patients worldwide. Generics are therapeutically equivalent to their branded counterparts with a lower price due to losing patent protection. The low cost of generic medications promotes patient affordability and contributes to lower per capita healthcare spending.
Basically, Teriflunomide is used to treat Multiple Sclerosis (MS) – a chronic disease that effects the central nervous system. The 14 mg film coated tablets developed and produced in Tiefenbacher Group`s own sites. Following this, the finished product is marketed by our partners, renowned international pharmaceutical companies. The product has already been successfully launched in the US, Canada, Mexico, and Australia – all with strict US Food and Drug Administration (FDA) standards.
Further markets will follow shortly to increase the global availability of our high-quality generic medicines even more. Tiefenbacher Group continuously making high-quality medicines better affordable, better global availability, and better than before.
TIEFENBACHER PHARMACEUTICALS, a part of Tiefenbacher Group, develops and commercializes generic, value added, and innovative pharmaceuticals as well as medical devices and e-health solutions worldwide. We provide over 180+ pharmaceutical products across various therapeutic categories in 10+ dosage forms. With our in-house product development and manufacturing, we can address specific therapeutic needs in unique formulations of prescription drugs (Rx) and over-the-counter (OTC) medicines for global markets.
For more information about our finished dosage forms (FDF) including highly potent drugs and e-health solutions, please contact Tiefenbacher Pharmaceuticals info@tiefenbacher.com or visit us on www.tiefenbacher-pharmaceuticals.com
About Tiefenbacher Group – Pioneering Healthcare since 1963
Tiefenbacher Group is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. From the initial idea to market access of high-quality medicines around the world: We distribute APIs and develop, produce, and register finished dosage forms (FDFs) including highly potent drugs as well as medical devices and e-health solutions. Our purpose is to improve people’s lives by making pharmaceuticals more affordable, more available, and better than ever before.
For further information about TIEFENBACHER GROUP and our solutions for better healthcare and our in-house capabilities to develop and commercialize pharmaceutical products for global markets (including highly potent drugs) please contact us by email info@tiefenbacher.com or visit us on www.tiefenbachergroup.com
State-of-the-art R&D facilities for powerful drug development
State-of-the-art R&D facilities for powerful drug development and manufacturing. New technology for generic, valued added, and innovative pharmaceuticals
We, at Tiefenbacher Group, go beyond R&D and manufacturing of pharmaceuticals with a commitment to quality, safety, and reliability that is anchored in everything we do. We continuously expand in novel technologies and capabilities to improve quality and boost productivity for powerful drug developement. Therefore we are pleased to announce that the foundation stone for one of our new Tiefenbacher Laboratories buildings has now been laid.
The new development block “Alfred”, named after the company founder Alfred E. Tiefenbacher, will provide 3360 m². In particularly, the building offers three floors of space for our new product development laboratory, the analysis laboratory, administrative offices and a canteen for employees. Moreover the complex is an important extension to the recently inaugurated development block for highly potent drugs.
This expansion also enables the Tiefenbacher Group to create the best technological conditions and at the same time a high degree of flexibility in the development of generics, value-added products and innovative medicines.
The building will take shape over the next few months and will be ready to be fully operational in about one year.
This investment follows Tiefenbacher Group’s strategy to strengthen its position as a global, fully integrated pharmaceutical company. With Tiefenbacher Laboratories, we own a state-of-the-art R&D and manufacturing site located in Hyderabad, India, for developing and producing high-quality pharmaceuticals including highly potent drugs.
The facilities are equipped with the most modern technologies and software and are subject to the strictest international quality standards. That also includes European (EMA) and US (FDA) approvals. Look forward to more updates on the progress in the coming months.
TIEFENBACHER PHARMACEUTICALS, a part of Tiefenbacher Group, develops and commercializes generic, value added, and innovative pharmaceuticals as well as medical devices and e-health solutions worldwide. We provide over 180+ pharmaceutical products across various therapeutic categories in 10+ dosage forms. With our in-house product development and manufacturing, we can address specific therapeutic needs in unique formulations of prescription drugs (Rx) and over-the-counter (OTC) medicines for global markets.
For more information about our finished dosage forms (FDF) including highly potent drugs and e-health solutions, please contact Tiefenbacher Pharmaceuticals info@tiefenbacher.com or visit us on www.tiefenbacher-pharmaceuticals.com
About Tiefenbacher Group – Pioneering Healthcare since 1963
Tiefenbacher Group is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. From the initial idea to market access of high-quality medicines around the world: We distribute APIs and develop, produce, and register finished dosage forms (FDFs) including highly potent drugs as well as medical devices and e-health-solutions. Our purpose is to improve people’s lives by making pharmaceuticals more affordable, more available, and better than ever before.
For further information about our solutions for better healthcare and our in-house capabilities to develop and commercialize pharmaceutical products (including highly potent drugs) and e-health-solutions for global markets, please contact us by email at info@tiefenbacher.com or visit us on: www.tiefenbacher-group.com
Tiefenbacher Pharmaceuticals Social Day 2023: Community Engagement
TIEFENBACHER PHARMACEUTICALS, a part of Tiefenbacher Group: Social Day 2023 – contribution through our social and community engagement in Hamburg
Tiefenbacher Pharmaceuticals employees get involved in the local community by volunteering with local charities and organizations.
Our employees take an active role in giving back to their communities by donating hours to help through a range of volunteer activities. We see ourselves as part of society and we are deeply committed to supporting the communities in which we are located. That is why we work with our employees to promote a diverse range of social initiatives that help tackle challenges at the local level. In this context, for our Tiefenbacher Group Social Day we have given our employees in hamburg time off so that they can get socially involved in an institution in the Hanseatic city.
We want to promote the common good in our beloved city and therefore supported the Tierpark Hagenbeck (zoo), the Sternbrücke Children’s Hospice, the Stiftung Das Rauhe Haus (child and youth welfare), the alsterdorf assistenz ost (institution for people with disabilities), the Hamburger Tierschutzverein (animal welfare association), and Hanseatic Help e.V. (support for refugees and homeless). Many thanks to all helpers and the organizer Marie-Theres Blumers for your numerous support and the great enthusiasm with which you are committed to your project.
TIEFENBACHER PHARMACEUTICALS, a part of Tiefenbacher Group, develops and commercializes generic, value added, and innovative pharmaceuticals as well as medical devices and e-health solutions worldwide. We provide over 180+ pharmaceutical products across various therapeutic categories in 10+ dosage forms. With our in-house product development and manufacturing, we can address specific therapeutic needs in unique formulations of prescription drugs (Rx) and over-the-counter (OTC) medicines for global markets (including highly potent drugs).
For more information about our finished dosage forms and healthcare solutions, please contact Tiefenbacher Pharmaceuticals: info@tiefenbacher.com or visit us on: www.tiefenbacher-pharmaceuticals.com
OYSTA: NEW WEBSITE ONLINE!
OYSTA: New website online – combining pharmaceuticals with e-health technology
We are happy to announce that we have launched a new web page for OYSTA – an innovative healthcare brand which we have developed together with our partner Ondosis.
With OYSTA, we aim to revolutionize the way how patients take their medicines by combining pharmaceuticals with e-health technology to enable intuitive, precise, and flexible dosing. It is a novel treatment approaches for attention deficit hyperactivity disorder (ADHD).
The new web page provides an overview of the purpose, function, and value of the unique product concept. For our community we have already recorded a sneak preview, but see for yourself and learn more about OYSTA on www.oysta-health.com.
TIEFENBACHER PHARMACEUTICALS, a part of Tiefenbacher Group, develops and commercializes generic, value added, and innovative pharmaceuticals as well as medical devices and e-health solutions worldwide. We provide over 180+ pharmaceutical products across various therapeutic categories in 10+ dosage forms. With our in-house product development and manufacturing, we can address specific therapeutic needs in unique formulations of prescription drugs (Rx) and over-the-counter (OTC) medicines for global markets (including highly potent drugs).
For more information about our finished dosage forms and healthcare solutions, please contact Tiefenbacher Pharmaceuticals: info@tiefenbacher.com or visit us on: www.tiefenbacher-pharmaceuticals.com
About Tiefenbacher Group – Pioneering Healthcare since 1963
Tiefenbacher Group is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. From the initial idea to market access of high-quality medicines around the world: We distribute APIs and develop, produce, and register finished dosage forms (FDF) including highly potent drugs as well as medical devices and e-health-solutions. Our purpose is to improve people’s lives by making pharmaceuticals more affordable, more available, and better than ever before.
For further information about our solutions for better healthcare and our in-house capabilities to develop and commercialize pharmaceutical products (including highly potent drugs) and e-health-solutions for global markets, please contact us by email at info@tiefenbacher.com or visit us on www.tiefenbachergroup.com
Tiefenbacher: Approval of manufacturing and laboratory facilities by Saudi Food and Drug Authority (SFDA)
Tiefenbacher: Own manufacturing and laboratory facilities successfully registered by the Saudi Food and Drug Authority (SFDA) for GCC region
The SFDA approves Tiefenbacher facilities! We are happy to announce that our manufacturing and laboratory facilities for oral solids at AET Laboratories in Hyderabad (India) have been successfully registered by the Saudi Food and Drug Authority (SFDA).
The registration is a great door opener for the full GCC region. The six Arab countries (Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates) is an important addition to our existing European (EMA) and international certifications (like the US FDA approval) and follows Tiefenbacher Group´s strategy to make our high-quality pharmaceuticals better available worldwide!
TIEFENBACHER PHARMACEUTICALS, a part of Tiefenbacher Group, develops and commercializes generic, value added, and innovative pharmaceuticals as well as medical devices and e-health solutions worldwide. We provide over 180+ pharmaceutical products across various therapeutic categories in 10+ dosage forms. With our in-house product development and manufacturing, we can address specific therapeutic needs in unique formulations of prescription drugs (Rx) and over-the-counter (OTC) medicines for global markets (including highly potent drugs).
For more information about our finished dosage forms and healthcare solutions, please contact Tiefenbacher Pharmaceuticals: info@tiefenbacher.com or visit us on: www.tiefenbacher-pharmaceuticals.com
About Tiefenbacher Group – Pioneering Healthcare since 1963
Tiefenbacher Group is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. From the initial idea to market access of high-quality medicines around the world: We distribute APIs and develop, produce, and register finished dosage forms (FDF) including highly potent drugs as well as medical devices and e-health-solutions. Our purpose is to improve people’s lives by making pharmaceuticals more affordable, more available, and better than ever before.
For further information about our solutions for better healthcare and our in-house capabilities to develop and commercialize pharmaceutical products (including highly potent drugs) and e-health-solutions for global markets, please contact us by email at info@tiefenbacher.com or visit us on www.tiefenbachergroup.com
TIEFENBACHER GROUP is committed to becoming climate neutral
Tiefenbacher Group is committed to becoming climate neutral by the end of 2025
We are pleased to share that TIEFENBACHER GROUP is committed to becoming climate neutral by the end of 2025*. As a value-driven healthcare company, dedicated to improving the life of patients worldwide, we recognize the importance of taking action to address the urgent climate crisis we face today. To achieve this goal, we are implementing a comprehensive sustainability strategy that includes the following measures, among others:
As our biggest driver of the carbon footprint is energy consumption, large-scale solar panels will be installed on our manufacturing facilities in Cyprus and India. Any electricity that cannot be produced in-house and must be purchased will be purely green electricity. In addition, we are implementing energy saving and efficiency measures – especially at our production sites. Furthermore, all company vehicles will be exclusively electric in the future. With these measures, we will already achieve a great interim goal: reducing our emissions by 80% by January 2024.
We believe that this is not only the right thing to do for the planet but also the right thing to do for our business. Being commercially successful and operating responsibly by becoming climate neutral is how we generate sustainable returns. We look forward to sharing more updates on our progress towards this important goal in the coming months and years.
*Scope 1 and 2 according to GHG as well as business travel and employee commuting
TIEFENBACHER PHARMACEUTICALS, a part of Tiefenbacher Group, develops and commercializes generic, value added, and innovative pharmaceuticals as well as medical devices and e-health solutions worldwide. We provide over 180+ pharmaceutical products across various therapeutic categories in 10+ dosage forms. With our in-house product development and manufacturing, we can address specific therapeutic needs in unique formulations of prescription drugs (Rx) and over-the-counter (OTC) medicines for global markets (including highly potent drugs).
For more information about our finished dosage forms and healthcare solutions, please contact Tiefenbacher Pharmaceuticals: info@tiefenbacher.com or visit us on: www.tiefenbacher-pharmaceuticals.com
About Tiefenbacher Group – Pioneering Healthcare since 1963
Tiefenbacher Group is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. From the initial idea to market access of high-quality medicines around the world: We distribute APIs and develop, produce, and register finished dosage forms (FDF) including highly potent drugs as well as medical devices and e-health-solutions. Our purpose is to improve people’s lives by making pharmaceuticals more affordable, more available, and better than ever before.
For further information about our solutions for better healthcare and our in-house capabilities to develop and commercialize pharmaceutical products (including highly potent drugs) and e-health-solutions for global markets, please contact us by email at info@tiefenbacher.com or visit us on www.tiefenbachergroup.com
Tiefenbacher: Renovating Headquarters in Hamburg
Tiefenbacher Pharmaceutical, a part of Tiefenbacher Group:
Renovating Headquarters in Hamburg /Germany – an agile, open-plan work space
Did you know that Tiefenbacher Group is currently renovating its headquarters in Hamburg, Germany as a response to the novel ways of working? We are excited to share the first results of the restructuring and are pleased to bring the first changes to life. The newly designed building will be a modern and innovative workspace that reflects our culture of entrepreneurship, professional excellence, and openness. The open-floor concept promotes creativity, collaboration, and teamwork among our employees. Also, the office concept provides for a maximum democratic approach in all the rooms, including the management stuff rooms. Additionally, the modernization allowed us for the new branding elements to be incorporated into the workspace. We believe that the new space, right on the banks of the river Elbe, provides a great working environment that supports the growth and wellbeing of our employees at the same time. With hybrid and at-home work the new normal for many people, Tiefenbacher wants to keep its workspace relevant and up to date.
Watch our short video to see the first changes with our new flexible work space. The interior turned out to be generally airy, transparent, filled with light. We´ll keep you posted on the progress and look forward to welcoming you to our new office space soon! The full modernization at our headquarters is expected to be completed in 2024.
TIEFENBACHER PHARMACEUTICALS AT DCAT 2023
Tiefenbacher Pharmaceuticals – a part of Tiefenbacher Group – at DCAT 2023: Thanks for meeting us in New York City!
DCAT week – one of the world´s most important pharma events – has just come to an end. It was four very successful and inspiring days for TIEFENBACHER in New York City. What a pleasure to present our latest product portfolio and innovations and to connect with existing and potential new partners. Check out our short video to get some impressions at DCAT 2023!
TIEFENBACHER PHARMACEUTICALS, a part of Tiefenbacher Group, develops and commercializes generic, value added, and innovative pharmaceuticals as well as medical devices and e-health solutions worldwide. We provide over 180+ pharmaceutical products across various therapeutic categories in 10+ dosage forms. With our in-house product development and manufacturing, we can address specific therapeutic needs in unique formulations of prescription drugs (Rx) and over-the-counter (OTC) medicines for global markets (including highly potent drugs).
For more information about our finished dosage forms (FDF) and healthcare solutions, please contact Tiefenbacher Pharmaceuticals: info@tiefenbacher.com or visit us on: www.tiefenbacher-pharmaceuticals.com
Tiefenbacher Pharmaceuticals New market launch: antihistamine Bilastine
New Market Launch: Tiefenbacher Pharmaceuticals successfully launches the antihistamine Bilastine for a market entry as over-the-counter (OTC) medicine in Germany
The allergy season is starting. Therefore we at Tiefenbacher Pharmaceuticals are thrilled to announce that we have successfully prepared the launch of the antihistamine Bilastine for a market entry as Over-the-counter (OTC) medicine in Germany.
Bilastine is an innovative anti-allergy medicine for patients suffering from allergic symptoms, such as hay fever and urticaria. It belongs to the non-sedating second-generation antihistamines. Generics are therapeutically equivalent to their branded counterparts with a lower price due to losing patent protection. The low cost of generic medications promotes patient affordability and contributes to lower per capita healthcare spending. The 20 mg tablets have been developed in TIEFENBACHER GROUP´s own laboratories. This product is currently marketed by our partner, a well-known international pharmaceutical company.
With this market entry we enable patients in Germany a better access to an important medicine. Moreover, it’s currently the only product of this type available in pharmacies without a prescription needed. Further generic launches in European markets are planned soon. Tiefenbacher Pharmaceuticals is committed to continuously making high-quality medicines better affordable, better global availability, and better than before.
TIEFENBACHER PHARMACEUTICALS, a part of Tiefenbacher Group, develops and commercializes generic, value added, and innovative pharmaceuticals as well as medical devices and e-health-solutions worldwide. We provide over 180+ pharmaceutical products across various therapeutic categories in 10+ dosage forms. With our in-house product development and manufacturing, we can address specific therapeutic needs in unique formulations of prescription drugs (Rx) and over-the-counter (OTC) medicines for global markets.
For more information about our finished dosage forms including highly potent drugs and e-healthcare solutions, please contact Tiefenbacher Pharmaceuticals info@tiefenbacher.com or visit us on www.tiefenbacher-pharmaceuticals.com
About Tiefenbacher Group – Pioneering Healthcare since 1963
Tiefenbacher Group is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. From the initial idea to market access of high-quality medicines around the world: We distribute APIs and develop, produce, and register finished dosage forms (FDFs) including highly potent drugs as well as medical devices and e-health solutions. Our purpose is to improve people’s lives by making pharmaceuticals more affordable, more available, and better than ever before.
For further information about TIEFENBACHER GROUP and our solutions for better healthcare and our in-house capabilities to develop and commercialize pharmaceutical products for global markets (including highly potent drugs) please contact us by email info@tiefenbacher.com or visit us on www.tiefenbachergroup.com
TIEFENBACHER GROUPS: Registration of manufacturing sites by UAE Ministry of Health
Tiefenbacher manufacturing sites have been successfully registered by the United Arab Emirates Ministry of Health
We are excited to announce that our two manufacturing sites at AET Laboratories in Hyderabad (India) and at Delorbis in Lefkosia (Cyprus) have been successfully registered by the United Arab Emirates Ministry of Health!
The United Arab Emirates (UAE) comprises seven Emirates located in the south east of the Arabian Peninsula: Abu Dhabi, Dubai, Sharjah, Ajman, Ras Al Khaimah, Umm al-Qaiwain and Fujairah. The approvals are based on our existing European and international certifications and follow Tiefenbacher Group´s strategy to make our high-quality pharmaceuticals better available worldwide!
TIEFENBACHER PHARMACEUTICALS, a part of Tiefenbacher Group, develops and commercializes generic, value added, and innovative pharmaceuticals as well as medical devices and e-health solutions worldwide. We provide over 180+ pharmaceutical products across various therapeutic categories in 10+ dosage forms. With our in-house product development and manufacturing, we can address specific therapeutic needs in unique formulations of prescription drugs (Rx) and over-the-counter (OTC) medicines for global markets (including highly potent drugs).
For more information about our finished dosage forms and healthcare solutions, please contact Tiefenbacher Pharmaceuticals: info@tiefenbacher.com or visit us on: www.tiefenbacher-pharmaceuticals.com